Name

T1D Exchange

Legal name

T1D Exchange

Website

https://t1dexchange.org

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Diabetes Clinical Research and Quality Improvement Services

NAICS

Health Care and Social Assistance (62), Other Ambulatory Health Care Services (6219), Ambulatory Health Care Services (621)

SIC

Services-Health Services (8000)

akta.pro primary industry

Type 1 Diabetes Care (HLAKADAB)

akta.pro secondary industries

HIE Platforms & Network Services (Community/Regional/National) (HLACABAB), Clinical Document & Data Exchange (C-CDA, CCD, Direct Messaging) (HLACABAI)

Keywords

• Diabetes patient registry
• Clinical research services
• Real-world evidence
• Quality improvement collaborative
• Healthcare data platform

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Research Grants and Funding: As a nonprofit organization, T1D Exchange relies primarily on grant funding from organizations such as The Leona M. and Harry B. Helmsley Charitable Trust to fund the T1DX-QI and other initiatives.
2. Custom Research Services: T1D Exchange collaborates with pharmaceutical companies and academic partners to conduct custom research studies, providing study design, data collection, analysis, and reporting services in exchange for research funding.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

T1D Exchange operates a long-term patient Registry enrolling people with type 1 diabetes to share lived experiences through surveys and participate in research, and the T1DX-QI quality improvement collaborative, a network of 60+ endocrinology centers sharing de-identified EHR data. It sells custom research services and study recruitment to pharmaceutical and academic partners, and produces clinical resources such as Change Packages, the Beta Cell Preservation Framework, and the HEAL health equity program.

Product overview

T1D Exchange is a nonprofit organization operating a platform of interconnected research and quality improvement products focused on type 1 diabetes. The core offerings include the T1D Exchange Registry (a long-term research study with 23,000+ participants), the T1DX-QI Portal (a secure data platform for the Quality Improvement Collaborative network of 60+ clinics), and Study Recruitment and Custom Research services for academic and industry partners. Additional products include the HEAL health equity program, Change Packages (clinical resources), Beta Cell Preservation framework, and engagement features like Question of the Day. These offerings work together to facilitate research and drive improvements in care for people with type 1 diabetes through real-world evidence generation and collaborative learning across a nationwide network of endocrine clinics.

Differentiator

Problem solved

Functional benefit

Brands

• T1D Exchange Registry: A long-term research study following people with T1D, with over 23,000 individuals participating.
• T1DX-QI (T1D Exchange Quality Improvement Collaborative)
• HEAL (Health Equity Improvement Lab)

Products and services

• T1D Exchange Registry A long-term research study that follows people with type 1 diabetes over time, with over 23,000 individuals participating. Registry participants share perspectives through surveys and can take part in additional research opportunities.
• T1DX-QI Portal A secure data platform that facilitates collaboration among T1DX-QI clinics using real-world EHR-based data to improve health outcomes among people living with type 1 diabetes.
• T1D Exchange Quality Improvement Collaborative (T1DX-QI) A collaborative network bringing together over 60 pediatric and adult endocrinology centers across the United States that care for over ~100,000 individuals with type 1 diabetes. Members share data via the T1D Quality Improvement platform to track baselines, outcomes, and improve care.
• Study Recruitment Services Connects researchers with engaged individuals and research-ready networks including the 23,000+ Registry participants and 75,000+ people impacted by T1D to accelerate study recruitment. Has supported 70+ studies.
• Custom Research Services Collaborative research design and execution services including study design, data collection, analysis, and reporting grounded in real-world experience from the T1D community, provided to pharmaceutical companies and academic partners under research agreements.
• HEAL Program (Health Equity Advancement Lab) A health equity improvement initiative that uses real-world data and collaboration to improve outcomes for people living with diabetes by addressing disparities in diabetes care.
• Beta Cell Preservation Framework A clinical and implementation framework from the T1DX-QI Beta Cell Preservation Working Group providing screening frameworks, staging protocols, and disease-modifying therapy workflow guidance.
• Change Packages Actionable resources documenting proven strategies and interventions from T1DX-QI centers including High-Risk T1D care, CGM Equity, Depression Screening, Access to Clinical Care, and Building QI Capacity.

Quantifiable outcome

• Children who started CGM within first six months after T1D diagnosis had lower A1Cs three years later compared to those who started later
• +3 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Partnerships

One partnership is on record.

• DYF (Diabetes Youth Families)minorStrategic or Co-development PartnerPartner in Campamento Familiar en Español, a Spanish-language diabetes camp program in partnership with UCSF to support Latinx families affected by T1D.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Jaeb Center for Health Research: Originally led the founding of the T1D Exchange Clinic Registry and Network in 2010. Operates a similar model of disease-specific patient registries and clinical research coordination, particularly in diabetes and ophthalmology, making it the closest operational analogue.
• JDRF (Breakthrough T1D): The largest T1D-focused nonprofit, funding research and advocacy globally. Comparable as a T1D-specific nonprofit that convenes researchers, clinicians, and patients, and overlapping with T1D Exchange in research funding and community engagement.
• Beyond Type 1: T1D-focused nonprofit operating programs, community, and grant-making with a digital-first model. Comparable as a T1D nonprofit that builds community engagement surfaces T1D Exchange leverages for research participation.
• Cystic Fibrosis Foundation: Operates the Cystic Fibrosis Foundation Patient Registry, one of the longest-running disease-specific registries, alongside a care center network and quality improvement program. Highly comparable as a disease-specific nonprofit that combines a patient registry, accredited care network, and QI collaborative to drive research and outcomes.
• diaTribe Foundation: Diabetes-focused nonprofit producing patient education, research coverage, and community programs. Overlaps with T1D Exchange on patient engagement, content, and surfacing real-world T1D experience to researchers and industry.

Emerging players

• Truveta: Health system-owned real-world data platform aggregating de-identified EHR data for research. Comparable in providing EHR-based real-world evidence to pharma, but operates across all conditions rather than T1D-specific.
• Tidepool: Diabetes data nonprofit offering a platform for visualizing data from CGM, insulin pumps, and CGMs. A listed T1D Exchange partner; comparable as a diabetes-focused nonprofit building data infrastructure used by people with T1D and the research community.

Broad incumbents

• Tempus: AI-enabled precision medicine company with large-scale clinical and molecular data across multiple disease areas. Comparable as a real-world evidence and AI-driven research platform serving pharma, though broader in scope than T1D Exchange.
• IQVIA: Global clinical research and real-world evidence leader. Overlaps with T1D Exchange on clinical trial recruitment support and real-world data analytics for pharma, though at vastly greater scale and across all therapeutic areas.
• Flatiron Health: Real-world evidence platform focused on oncology, built from EHR data. Operates a similar model of aggregating de-identified clinical data from provider networks to support pharma research and regulatory submissions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/t1dexchange
• Facebookfacebook.com/MyGlu
• LinkedInlinkedin.com/company/2318764

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about T1D Exchange